Genmab — Juli 2025
-
yes, i was confused when the last update of the GEN1059 deleted the arm with Pembro so shortly after that abstract https://clinicaltrials.gov/study/NCT06150183?tab=history&a=13&b=14&compareMode=sideBySide#version-content-panel , worried it was the end of 1059. Now it seems they just switched Pembro with BNT327 and immediately hope springs again lol
-
Fra MW "Genmab har fået hævet kursmålet til 1916 kr. fra 1785 kr. hos storbanken Goldman Sachs, som dog holder fast i sin neutrale anbefaling af aktien.
Det fremgår af Bloomberg News.
Trods den neutrale anbefaling indikerer kursmålet 32,2 pct. potentielt afkast over de kommende 12 måneder, efter at Genmab-aktien onsdag steg 4,7 pct. til 1449,50 kr."
-
the Tepezza EMA EPAR - Public assessment report for those interested -153 pages- https://www.ema.europa.eu/en/documents/assessment-report/tepezza-epar-public-assessment-report_en.pdf
-
Roche YTD June 2025 https://assets.roche.com/f/176343/x/3e163d97e6/250724_ir_hy.pdf CHF mn Ocrevus 3,506 8% , Columvi 123 88% , Lunsumio 48 33%
-
I dag, torsdag den 24. juli 2025, er en helt speciel dag for mange aktieinvestorer. For C25 er efter en hård 2025 endelig i plus igen. Helge Larsen ser på årsagerne og omtaler Novo Nordisk, Zealand Pharma, ISS, Vestas, Carlsberg og Bavarian Nordic. Og så slutter han af med flere gode nyheder, her fra Anavex, som i går steg 20 procent. Kort video: https://proinvestor.com/boards/127342/
-
Small new trial - A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) https://clinicaltrials.gov/study/NCT07082868
-
Sanofi's Sarclisa Combination Gets EU Approval For Treating Newly Diagnosed Multiple Myeloma https://proinvestor.com/investornyt/1342936/sanofis-sarclisa-combination-gets-eu-approval-for-treating-newly-diagnosed-multiple-myeloma
-
A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockade https://www.nature.com/articles/s41598-025-11990-z
-
this is what it said last august24: Following a strategic evaluation of GEN1053 within the context of
Genmab’s and BioNTech’s portfolios, a decision was made to discontinue the Phase 1/2 clinical trial
(NCT05435339) of GEN1053 in solid tumors. Preclinical activities remain ongoing. -
Godmorgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind